-
Company Profile
![]()
Clinuvel Pharmaceuticals Ltd – Company Profile
Clinuvel Pharmaceuticals Ltd (Clinuvel Pharmaceuticals) is a biopharmaceutical company which focuses on the development of drugs for the treatment of light related severe skin disorders. The company’s lead product candidate, Scenesse (afamelanotide) is a first-in-class drug targeting erythropoietic protoporphyria (EPP) and is approved in Europe, Australia and the US for treating adult EPP patients. Its other products under development includes CUV9900 and VLRX001 among others. Clinuvel Pharmaceuticals also focused on developing a pediatric formulation of Scenesse for EPP and OTC...
Add to Basket -
Company Profile
![]()
Aura Minerals Inc – Company Profile
Aura Minerals Inc (Aura) is a precious metals and mining company that carries out the development and operation of gold and base metal projects in South America, Central America, and North America. It focuses on the mining and production of copper, silver, and gold. The company owns 100% interest in the Aranzazu Copper Mine in Mexico, the San Andres Gold Mine in Honduras and the Gold Road mine in the US. It holds 49% interests in EPP mines including Ernesto...
Add to Basket -
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – afamelanotide acetate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry afamelanotide acetate Drug Details Afamelanotide (Scenesse) is an analog of the peptide hormone alpha-melanocyte...
-
Sector Analysis
![]()
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Malaysia
GlobalData, the industry analysis specialist, has released its latest report: “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Malaysia”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Malaysia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built...
-
Product Insights
![]()
Porphyria (Erythropoietic Protoporphyri) Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Porphyria (Erythropoietic Protoporphyri) Global Clinical Trials Review, H1, 2018" provides an overview of Porphyria (Erythropoietic Protoporphyri) clinical trials scenario. This report provides top line data relating to the clinical trials on Porphyria (Erythropoietic Protoporphyri). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.